Developer docs
API playgroundTry for free, no card

Search company profiles

JOTEC

Full company profile

uuid000gxac

Namestring
JOTEC
Websiteurl
jotec.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

JOTEC is a privately held German medical device company headquartered in Hechingen, founded in 2000, operating with 251–500 employees. According to its firmographic profile, JOTEC develops, produces, and markets medical devices for the treatment of aortic and peripheral vascular disease. Its portfolio of branded devices historically centers on endovascular stent graft systems and complementary delivery/accessory tools, including the E-TEGRA abdominal aortic stent graft system, the E-LIAC stent graft system for peripheral/abdominal use, the E-vita Open NEO hybrid stent graft for the aortic arch, the E-xtra Design MultiBranch and E-NSIDE TAAA multibranch systems for thoracoabdominal repair, the E-XPAND stent graft balloon catheter, and the E-WIRE guidewire. These product lines now appear within the Artivion (formerly CryoLife) aortic platform's public product catalog, indicating that JOTEC's commercial assets have been folded into a larger corporate parent, although the transaction itself is not explicitly described in the provided source data.

JOTEC's revenue mechanics are not disclosed in the source material. As a manufacturer of Class III implantable vascular devices, the typical business model involves direct sales and distributor relationships with hospitals and specialist cardiac/vascular surgeons, premium implant-level pricing, and a regulatory-clearance-driven go-to-market cadence. The company does not expose any public API, SDK, or digital platform (api_exists: false), and no proprietary software, AI/ML capabilities, or data flywheel is documented. Customer concentration, pricing, partnerships, and sales-channel mix are likewise not provided, leaving meaningful gaps in the investment picture.

The most strategically relevant observable signal is that JOTEC's device family is now embedded within a broader aortic franchise alongside adjacent arch and thoracoabdominal products (NEXUS family, AMDS Hybrid Prosthesis, CryoValve, BioGlue) and within a clinical pipeline that includes the AMDS PERSEVERE trial (enrollment completed November 2023, FDA Humanitarian Device Exemption granted December 2024, late-breaking one-year data presented January 2025). This positions JOTEC's assets within an ongoing aortic consolidation strategy, but JOTEC-specific financials, headcount trend, and standalone strategic moves are not present in the supplied data.

Short descriptiontext

JOTEC is a German privately held medical device company, founded in 2000 in Hechingen, that develops, produces, and markets implantable aortic and peripheral vascular devices — primarily stent graft systems — for cardiac and vascular surgeons and hospital systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHechingen, Germany
HQ citystring
Hechingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
vascular medical devices, aortic stent grafts, endovascular repair, peripheral vascular devices, cardiovascular implants
Industry3 codes
1Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts
CodeHLAHAFAFPrimaryYes
2Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
CodeHLAHAFAEPrimaryNo
3Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
CodeHLAHAFAKPrimaryNo
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Vascular Medical Devices
Social media profiles2 records
Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

JOTEC develops, produces, and markets medical devices for aortic and peripheral vascular disease. The company's portfolio centers on endovascular stent graft systems and hybrid prostheses used in the treatment of aortic and peripheral vascular conditions, including devices for abdominal aortic repair, iliac and peripheral vascular applications, thoracoabdominal repair, and aortic arch procedures.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information for JOTEC is present in the provided source data. The sources contain medical device market analysis (PTA Balloon Catheters) and Artivion company information (aortic medical devices including heart valves, allografts, stent grafts, and surgical sealants), but no references to JOTEC products, services, or company details.

Product and service1 record
1Aortic and Peripheral Vascular Medical Devices
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medical-device conglomerate with vascular surgery grafts (including open and hybrid aortic solutions). Competes in adjacent aortic and peripheral segments with broader hospital capital equipment exposure than JOTEC.

TypeEmerging player
Description

Developer of catheter-based thrombectomy and peripheral vascular intervention devices. Competes with JOTEC in peripheral vascular and catheter-delivered therapies, though with a different procedural focus.

TypeBroad incumbent
Description

Abbott's cardiovascular division offers peripheral intervention and structural heart products. Competes with JOTEC in peripheral vascular intervention and shares the same hospital customer base for endovascular procedures.

TypeBroad incumbent
Description

Global medical device leader with the Endurant abdominal and Valiant thoracic stent graft systems. Direct competitor in EVAR/TEVAR with substantially larger R&D, clinical-evidence, and commercial reach versus JOTEC.

TypeDirect peer
Description

Aortic and peripheral division of Terumo, formed from the Vascutek and Bolton Medical combinations. Competes head-to-head with JOTEC in open surgical grafts and thoracic/abdominal stent grafts.

TypeEmerging player
Description

Specialty vascular surgery device company with a portfolio of biologic patches, carotid shunts, and catheters. Smaller and more focused than JOTEC, but competes in adjacent peripheral and vascular surgery niches.

TypeDirect peer
Description

Developer of the Zenith family of aortic stent grafts and a broad peripheral vascular intervention portfolio. Direct competitor across abdominal, thoracic, and peripheral vascular segments where JOTEC operates.

TypeDirect peer
Description

Privately held manufacturer of the Excluder (AAA) and TAG/Conformable GORE TAG (TAA) endovascular stent graft families. Closest direct competitor to JOTEC's E-tegra and thoracic platforms, with deep surgeon relationships and a long clinical track record.

TypeBroad incumbent
Description

Diversified medical-technology manufacturer with peripheral vascular, surgical, and endovascular product lines. Overlaps with JOTEC in peripheral vascular intervention and catheters.

TypeBroad incumbent
Description

Parent company of JOTEC and a focused aortic franchise including heart valves, allografts, and stent grafts (e.g., AMDS, On-X, NEXUS). While a parent rather than a peer in the strict sense, the aortic portfolio overlaps substantially with JOTEC's offerings and provides the closest reference benchmark.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JOTEC

Vascular Medical Devicesjotec.com

JOTEC is a German privately held medical device company, founded in 2000 in Hechingen, that develops, produces, and markets implantable aortic and peripheral vascular devices — primarily stent graft systems — for cardiac and vascular surgeons and hospital systems.

What JOTEC does

JOTEC is a privately held German medical device company headquartered in Hechingen, founded in 2000, operating with 251–500 employees. According to its firmographic profile, JOTEC develops, produces, and markets medical devices for the treatment of aortic and peripheral vascular disease. Its portfolio of branded devices historically centers on endovascular stent graft systems and complementary delivery/accessory tools, including the E-TEGRA abdominal aortic stent graft system, the E-LIAC stent graft system for peripheral/abdominal use, the E-vita Open NEO hybrid stent graft for the aortic arch, the E-xtra Design MultiBranch and E-NSIDE TAAA multibranch systems for thoracoabdominal repair, the E-XPAND stent graft balloon catheter, and the E-WIRE guidewire. These product lines now appear within the Artivion (formerly CryoLife) aortic platform's public product catalog, indicating that JOTEC's commercial assets have been folded into a larger corporate parent, although the transaction itself is not explicitly described in the provided source data.

JOTEC's revenue mechanics are not disclosed in the source material. As a manufacturer of Class III implantable vascular devices, the typical business model involves direct sales and distributor relationships with hospitals and specialist cardiac/vascular surgeons, premium implant-level pricing, and a regulatory-clearance-driven go-to-market cadence. The company does not expose any public API, SDK, or digital platform (api_exists: false), and no proprietary software, AI/ML capabilities, or data flywheel is documented. Customer concentration, pricing, partnerships, and sales-channel mix are likewise not provided, leaving meaningful gaps in the investment picture.

The most strategically relevant observable signal is that JOTEC's device family is now embedded within a broader aortic franchise alongside adjacent arch and thoracoabdominal products (NEXUS family, AMDS Hybrid Prosthesis, CryoValve, BioGlue) and within a clinical pipeline that includes the AMDS PERSEVERE trial (enrollment completed November 2023, FDA Humanitarian Device Exemption granted December 2024, late-breaking one-year data presented January 2025). This positions JOTEC's assets within an ongoing aortic consolidation strategy, but JOTEC-specific financials, headcount trend, and standalone strategic moves are not present in the supplied data.

JOTEC firmographics

Firmographics
Name
JOTEC
Website
https://jotec.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
251–500 employees
Short description
JOTEC is a German privately held medical device company, founded in 2000 in Hechingen, that develops, produces, and markets implantable aortic and peripheral vascular devices — primarily stent graft systems — for cardiac and vascular surgeons and hospital systems.
Ownership category
akta.pro rank

JOTEC industry classification

Industry
Product category
Vascular Medical Devices
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF)
akta.pro secondary industries
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

  • Vascular medical devices
  • Aortic stent grafts
  • Endovascular repair
  • Peripheral vascular devices
  • Cardiovascular implants

Where JOTEC is headquartered

Location

Headquarters

HQ city
Hechingen
HQ country
Germany
HQ region
Europe

Markets served

JOTEC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

JOTEC product offering

Product offering

Core offering

JOTEC develops, produces, and markets medical devices for aortic and peripheral vascular disease. The company's portfolio centers on endovascular stent graft systems and hybrid prostheses used in the treatment of aortic and peripheral vascular conditions, including devices for abdominal aortic repair, iliac and peripheral vascular applications, thoracoabdominal repair, and aortic arch procedures.

Product overview

No product information for JOTEC is present in the provided source data. The sources contain medical device market analysis (PTA Balloon Catheters) and Artivion company information (aortic medical devices including heart valves, allografts, stent grafts, and surgical sealants), but no references to JOTEC products, services, or company details.

Differentiator

Problem solved

Functional benefit

Products and services

  • Aortic and Peripheral Vascular Medical Devices

Companies that use JOTEC

Customer profile

Ideal customer profiles1 record

JOTEC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

JOTEC partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

JOTEC competitors and assessment

Company assessment

Broad incumbents

  • Getinge (Maquet): Medical-device conglomerate with vascular surgery grafts (including open and hybrid aortic solutions). Competes in adjacent aortic and peripheral segments with broader hospital capital equipment exposure than JOTEC.
  • Abbott Vascular: Abbott's cardiovascular division offers peripheral intervention and structural heart products. Competes with JOTEC in peripheral vascular intervention and shares the same hospital customer base for endovascular procedures.
  • Medtronic: Global medical device leader with the Endurant abdominal and Valiant thoracic stent graft systems. Direct competitor in EVAR/TEVAR with substantially larger R&D, clinical-evidence, and commercial reach versus JOTEC.
  • Becton, Dickinson and Company (BD): Diversified medical-technology manufacturer with peripheral vascular, surgical, and endovascular product lines. Overlaps with JOTEC in peripheral vascular intervention and catheters.
  • Artivion: Parent company of JOTEC and a focused aortic franchise including heart valves, allografts, and stent grafts (e.g., AMDS, On-X, NEXUS). While a parent rather than a peer in the strict sense, the aortic portfolio overlaps substantially with JOTEC's offerings and provides the closest reference benchmark.

Emerging players

  • Penumbra: Developer of catheter-based thrombectomy and peripheral vascular intervention devices. Competes with JOTEC in peripheral vascular and catheter-delivered therapies, though with a different procedural focus.
  • LeMaitre Vascular: Specialty vascular surgery device company with a portfolio of biologic patches, carotid shunts, and catheters. Smaller and more focused than JOTEC, but competes in adjacent peripheral and vascular surgery niches.

Direct peers

  • Terumo Aortic: Aortic and peripheral division of Terumo, formed from the Vascutek and Bolton Medical combinations. Competes head-to-head with JOTEC in open surgical grafts and thoracic/abdominal stent grafts.
  • Cook Medical: Developer of the Zenith family of aortic stent grafts and a broad peripheral vascular intervention portfolio. Direct competitor across abdominal, thoracic, and peripheral vascular segments where JOTEC operates.
  • W. L. Gore & Associates (Gore Medical): Privately held manufacturer of the Excluder (AAA) and TAG/Conformable GORE TAG (TAA) endovascular stent graft families. Closest direct competitor to JOTEC's E-tegra and thoracic platforms, with deep surgeon relationships and a long clinical track record.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

JOTEC social profiles

Digital presence

JOTEC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JOTEC leadership team

Management profile

Number of profiles

JOTEC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JOTEC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JOTEC

What does JOTEC do?

JOTEC develops, produces, and markets medical devices for aortic and peripheral vascular disease. The company's portfolio centers on endovascular stent graft systems and hybrid prostheses used in the treatment of aortic and peripheral vascular conditions, including devices for abdominal aortic repair, iliac and peripheral vascular applications, thoracoabdominal repair, and aortic arch procedures.

Is JOTEC a public or private company?

JOTEC is a private company. It is classified as unknown and is currently operating.

When was JOTEC founded?

JOTEC was founded in 2000. It employs 251 to 500 people.

Where is JOTEC based?

JOTEC is headquartered in Hechingen, Germany, in the Europe region.

Who are JOTEC's main competitors?

Broad incumbents on record are Getinge (Maquet), Abbott Vascular, Medtronic, Becton, Dickinson and Company (BD) and Artivion. Emerging players are Penumbra and LeMaitre Vascular. Direct peers are Terumo Aortic, Cook Medical and W. L. Gore & Associates (Gore Medical).

Does JOTEC have an API?

No public API is recorded for JOTEC.

What industry is JOTEC in?

JOTEC's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAF, Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCryoLife Receives CE Mark for E-vita Open NEO™ Hybrid Stent GraftCryoLife, Inc. has received CE Mark approval for its E-vita Open NEO hybrid stent graft system, designed for the treatment of aortic arch disease including aneurysms and dissections. The device enables a one-stage surgical procedure combining open arch repair with endovascular descending thoracic repair, reducing costs and eliminating the need for a second surgery. The technology, which will often be used alongside JOTEC's E-nya thoracic stent graft, is anticipated to benefit approximately 7,000 patients treated annually in Europe, the Middle East, and Africa.PR NewswireCryoLife Receives CE Mark for E-nya Thoracic Stent GraftCryoLife, Inc. announced it has received CE Mark approval for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending thoracic aorta, including thoracic aortic aneurysms and dissections. The E-nya system, built upon JOTEC's thoracic endovascular aortic repair expertise, will be manufactured at CryoLife's facility in Hechingen, Germany, and targets the estimated $600 million global thoracic aortic disease market. The company stated the next-generation low-profile device gives physicians more options and control while treating both simple and challenging anatomies, enhancing its position in the growing EU aortic repair market.PR NewswireCryoLife Receives CE Mark for E-nside Thoraco-abdominal Stent GraftCryoLife, Inc. announced receipt of CE Mark approval for its E-nside TAAA multibranch stent graft system, an off-the-shelf pre-cannulated device for the endovascular treatment of thoraco-abdominal aneurysms. The approval positions the company in a market treating approximately 20,000 patients annually, valued at roughly $215 million worldwide, with manufacturing to be conducted at CryoLife's facility in Hechingen, Germany. The device leverages JOTEC's seven-year experience with over 2,000 implants and is designed to reduce procedure times by eliminating the up-to-90-day wait for custom-made stent grafts.PR NewswireCryoLife Reports Fourth Quarter and Full Year 2018 Financial ResultsCryoLife, Inc. reported fourth quarter 2018 revenues of $67.8 million, representing 28% year-over-year growth, with full year 2018 revenues of $262.8 million, up 39% compared to 2017. The strong growth was primarily driven by JOTEC revenues of $16.7 million in Q4 2018 versus $4.1 million in Q4 2017, and 25% full year non-GAAP revenue growth from the JOTEC product line following its acquisition in December 2017. Despite the revenue growth, the company reported a GAAP net loss of ($3.8) million for 2018 compared to net income of $3.7 million in 2017, with non-GAAP net income declining to $9.7 million from $16.7 million due to higher integration costs and pipeline investment.PR NewswireCryoLife Reports Third Quarter 2018 ResultsCryoLife reported strong Q3 2018 results with total revenues up 47% to $64.6 million, driven by $15.0 million in JOTEC revenues and 36% growth in On-X products. Net income was $1.6 million or $0.04 per diluted share on a GAAP basis, and the company raised its full-year 2018 revenue guidance to $261.5-$262.5 million. The CEO cited successful market share gains and new account growth as momentum drivers heading into Q4.PR NewswireCryoLife Reports Second Quarter 2018 ResultsCryoLife, Inc. reported second quarter 2018 financial results with total revenues of $68.5 million, a 43% increase compared to $47.8 million in Q2 2017, driven primarily by $17.2 million in JOTEC revenues following its acquisition in December 2017. Net income declined to $226,000 ($0.01 per diluted share) from $3.2 million ($0.09 per diluted share) year-over-year, though non-GAAP net income was $3.9 million ($0.10 per diluted share). The company raised its full-year 2018 revenue guidance to $256-260 million and expects continued business momentum based on strong On-X and JOTEC product performance.PR NewswireCryoLife Reports First Quarter 2018 ResultsCryoLife, Inc. reported first quarter 2018 financial results with total revenues of $61.9 million, a 37% increase compared to the same period in 2017, driven primarily by $14.5 million in revenues from the recently acquired JOTEC business. The company posted a GAAP net loss of $3.9 million, or $0.11 per diluted share, versus net income of $2.2 million in Q1 2017, though non-GAAP net income was $793,000, or $0.02 per diluted share. Management reiterated its full-year 2018 revenue guidance of $250 to $256 million and expressed confidence in the JOTEC integration remaining on track.PR NewswireCryoLife Reports Fourth Quarter and Full Year 2017 ResultsCryoLife, Inc. reported fourth quarter 2017 revenues of $52.8 million, a 17% increase year-over-year, with full year 2017 revenues reaching $189.7 million, up 5% from the prior year. The company completed its acquisition of JOTEC in the fourth quarter, which contributed $4.1 million in December revenues, while achieving double-digit revenue growth in BioGlue, On-X, and tissue processing. For full year 2017, GAAP net income was $3.7 million compared to $10.8 million in 2016, though the company issued 2018 guidance projecting total revenues of $250-256 million.PR NewswireCryoLife Completes Acquisition of JOTECCryoLife, Inc. announced the completion of its acquisition of JOTEC AG, a German-based privately-held company, on December 1, 2017. JOTEC AG specializes in endovascular stent grafts and cardiac and vascular surgical grafts focused on aortic repair. The acquisition adds technologically differentiated products to CryoLife's portfolio, which already markets products for treating aortic disease in more than 80 countries.PR NewswireCryoLife Reports Third Quarter 2017 ResultsCryoLife reported third-quarter 2017 revenues of $44.0 million, a 3% decrease from the prior year, primarily due to distributor terminations and weather impacts associated with its planned acquisition of JOTEC. The company announced a definitive agreement to acquire JOTEC, which it expects to close in late 2017, aiming to expand its product portfolio and revenue growth. CryoLife simultaneously revised its full-year 2017 financial guidance downward to reflect these transitional disruptions.